As of December 31, 2020, Sinovac Biotech Ltd. has 99.29M shares outstanding.
| Shares Outstanding | 99.29M |
As of December 31, 2020, Sinovac Biotech Ltd. trades at an EV/EBITDA multiple of 24.93 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.28 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 27.99 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Sinovac Biotech Ltd. trades at an EV/FCF ratio of 18.10, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.
| EV / Sales | 5.28 |
| EV / EBITDA | 24.93 |
| EV / EBIT | 27.99 |
| EV / FCF | 18.10 |
As of December 31, 2020, Sinovac Biotech Ltd. maintains a current ratio of 2.30, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 12.18, indicating elevated leverage, while an interest coverage ratio of 151.30 demonstrates strong ability to service its debt obligations.
| Current Ratio | 2.30 |
| Quick Ratio | 2.10 |
| Debt / Equity | 12.18 |
| Debt / EBITDA | 0.62 |
| Interest Coverage | 151.30 |
Over the twelve months ended December 31, 2020, Sinovac Biotech Ltd. posted a return on equity (ROE) of 20.06, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 22.18 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 9.38, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.52, useful for judging operating efficiency across full business cycles. Inventory turnover of 1.01 indicates how many times Sinovac Biotech Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | 20.06 |
| Return on Assets (ROA) | 9.38 |
| Return on Invested Capital (ROIC) | 22.18 |
| Return on Capital Employed (ROCE) | 4.52 |
| Inventory Turnover | 1.01 |
These figures cover the twelve months ended December 31, 2020. That works out to an effective tax rate of 14.51, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.
| Effective Tax Rate | 14.51 |
These figures are as of the close on March 10, 2025.
| 50-Day Moving Average | 6.47 |
Over the twelve months ended December 31, 2020, Sinovac Biotech Ltd. posted a gross margin of 86.84, reflecting its pricing power and cost economics. The operating margin of 42.26 and net profit margin of 21.61 provide insight into operational efficiency.
| Gross Margin | 86.84 |
| Operating Margin | 42.26 |
| Pretax Margin | 42.42 |
| Profit Margin | 21.61 |
| EBITDA Margin | 43.05 |
These figures cover the twelve months ended December 31, 2020. The dividend payout ratio of -2.37 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.
| Payout Ratio | -2.37 |
As of December 31, 2020, Sinovac Biotech Ltd. has an Altman Z-Score of 1.31, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.31 |
Already premium?